FDA panel wants limits on hydrocodone painkillers

January 25, 2013 in Medications

Federal health advisors want new restrictions on hydrocodone, the highly addictive ingredient found in Vicodin and other widely abused prescription painkillers.

The 's panel of specialists voted to subject hydrocodone drugs to the same restrictions as narcotics like oxycodone and morphine.

Hydrocodone is sold in combination pills like Vicodin, which mixes the drug with non-addictive painkillers like acetaminophen. Doctors prescribe the medicines to treat pain from injuries, surgery, arthritis and other ailments.

Hydrocodone consistently ranks as the first or second most-abused medicine in the U.S. each year, according to the Drug Enforcement Agency.

The DEA has asked the FDA to reclassify hydrocodone as a schedule III drug, limiting which kinds of medical professionals can write a prescription and how many times it can be refilled.

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created 15 hours ago | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created 16 hours ago | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Breathing exercises help veterans find peace after war, scholar says

(Medical Xpress)—Research by Stanford scholar Emma Seppala at the Center for Compassion and Altruism Research and Education found that post-traumatic stress disorder decreased in veterans who participated ...

Do doctors understand the individualisation of treatments?

The individualisation of drug treatments to support patients to self-manage their conditions is a concept that sits at the heart of policy, but a recent study in BMJ Open shows that there is no concrete defini ...

Reducing experimental inflammatory arthritis

(Medical Xpress)—UCD researchers led by Conway Fellow, Professor David Brayden in UCD School of Veterinary Medicine have successfully reduced inflammation in the swollen arthritic knees of a murine model using a novel nanoparticle.